In the News
Hackensack Meridian Health’s Tackle Kids Cancer Celebrates 10 Years of Support in the Fight Against Pediatric Cancer
Today, Hackensack Meridian Health will celebrate the tenth anniversary of its pediatric cancer initiative, Tackle Kids Cancer, which has raised more than $26 million since its inception to support patients and their families throughout New Jersey and beyond.
The program raises funds in support of research, treatment options and patient care programs for the organization’s two children’s hospitals: Hackensack Meridian Joseph M. Sanzari Children’s Hospital, located at Hackensack Meridian Hackensack University Medical Center in Hackensack, NJ, and Hackensack Meridian K. Hovananian Children’s Hospital, located at Hackensack Meridian Jersey Shore University Medical Center, in Neptune, NJ.
Eli Manning, former New York Football Giants quarterback and two-time Superbowl champion, has served as #TeamTKC Captain since the program’s launch. Through a partnership with the New York Giants and a shared tradition deeply rooted in helping the community, Manning became ambassador of TKC and has been instrumental in raising the funds that sustain the program’s ability to support pediatric cancer research, clinical trials, patient care and unique survivorship programs.
“We recognized early on as a network that more needed to be done to fight cancer, especially when it comes to children’s cancers,” said Robert Garrett, the CEO of Hackensack Meridian Health. “Only a small percentage of the national cancer research budget is dedicated to pediatric cancer, and so back in 2015, we partnered with the New York Football Giants to help raise awareness for the urgent need to find a cure. We were so fortunate that Eli was immediately drawn to this initiative and has been our greatest champion. We are so grateful to him, and everyone who has supported Tackle Kids Cancer throughout the years, and are proud of what we have achieved together.”
inspired by many scout troops, youth sports teams and schools that raised money for TKC, Manning launched Eli’s Challenge in 2016, matching gifts every year to encourage and support individual donors and group fundraisers. Since its inception, Eli’s Challenge has raised nearly $1.5 million through community peer-to-peer fundraisers.
“Working with Tackle Kids Cancer has been incredibly rewarding,” says Manning. “Those kids inspire me every day, and it’s because of them that I’m motivated to keep pushing forward. We need to find a cure for pediatric cancer, because no child should have to go through what they do. They deserve to just be kids, and I will keep on this mission until no more children or families have to receive that terrible news. For the tenth anniversary of Tackle Kids Cancer, I hope people will join me in making a gift to this important initiative.”
Likewise, the research being conducted at the Zakrzewski Laboratory at the CDI is investigating new immunotherapy treatments for pediatric cancer and is funded through philanthropy, the American Cancer Society and the National Cancer Institute. One barrier to progress in cancer immunotherapy has been the lack of unique markers that distinguish tumor cells from normal cells. Johannes Zakrzewski, M.D., and Ashley Varkey, D.O., identified novel sugar and lipid signatures present only on tumor cells, and they are using these as targets to develop new immunotherapies to treat children with aggressive blood cancers.
“The work being done by our physicians in the field of pediatric oncology is world-class, with families from all over the region - and even across the country and world - flocking to our facilities to get their children the best care,” said Alfred Gillio, M.D., director of the Children’s Cancer Institute at Joseph M. Sanzari Children’s Hospital and Jessica Scerbo, M.D., section chief, Pediatric Hematology/Oncology at K. Hovnanian Children's Hospital, in a joint statement. “We are able to offer a variety of clinical trials, conduct ground-breaking research, create new programs, bolster existing initiatives and offer support to entire families, and so much of that has been made possible thanks to the generosity of donors. We are so grateful for the support we have received over the last 10 years, and are hopeful that this year will be our most successful year ever.”
Funding from the program, under the auspices of the Hackensack Meridian Health Foundation has also been used to start an Adolescent and Young Adult program for teenagers and those in their young 20s who are fighting cancer; fertility preservation programs; and even breakthroughs in sickle cell disease, including curing the first patients in New Jersey, to name just a few important initiatives that have been made possible thanks to donor support.
“Tackle Kids Cancer is such an important initiative and has brought so much hope and healing to many families,” says Joyce P. Hendricks, president and chief development officer for Hackensack Meridian Health Foundation. “We are so grateful to everyone who has partnered with us over the last 10 years to make an impact on this dreadful disease. We hope that in 10 more years, we can be celebrating a cure, but until that time, philanthropy is needed more than ever. Our intention is to use the 10 year anniversary to increase awareness and support for Tackle Kids Cancer so that we can change the lives of even more children and give others a future free from cancer.”
To make a gift in support of Tackle Kids Cancer, visit tacklekidscancer.org. To create a peer-to-peer fundraiser, visit GiveHMH.org/ElisChallenge. To hear more about funding opportunities at Joseph M. Sanzari Children’s Hospital, email Natalie Tessoun at natalie.tessoun@hmhn.org, or Ellen Hahn at ellen.hahn@hmhn.org for funding opportunities at K. Hovnanian Children’s Hospital.
About Dr. Andre Goy, M.D., M.S.
Andre Goy, M.D. is Physician-in-Chief for Hackensack Meridian Health Oncology Services and Chairman of John Theurer Cancer Center as well as Founding Chair of Oncology at the Hackensack Meridian Health (HMH) School of Medicine and Professor of Medicine at Georgetown University in Washington, DC.
HMH is New Jersey’s largest Healthcare system (18 hospitals and over 38,000 employees) and John Theurer Cancer Center, its flagship cancer program is recognized as the state's largest and #1 in our state as well as among the Top 50 cancer programs by US News and World Reports. JTCC is a member of the NCI-designated Lombardi Comprehensive Cancer Center Consortium and also a member of the Memorial Sloan Kettering / MSKCC - Hackensack Meridian Health partnership.
Dr. Goy also leads the Lymphoma Program at JTCC and is widely known for his work particularly in aggressive lymphoma and mantle cell lymphoma, especially around novel therapies, immunotherapy, and CAR T cells. He has served on the NCI steering committee for lymphoma and on the Scientific Advisory Board of the Lymphoma Research Foundation. Dr. Goy has published more than 250 peer-reviewed papers and serves as a reviewer for many journals in the field including the New England Journal of Medicine, the Journal of Clinical Oncology, and Blood, among others.
Dr Goy brought the best-in-class genomics liquid biopsies technology platform to support precision and personalized medicine in cancer patients. He is a co-founder of COTA Healthcare, an analytics company to help rationalize treatment decisions in cancer care, to improve each patient outcome and help bring clarity for physicians and patients at the point of decision of care and bring value through smarter medicine (ie what is my best option now, and what is the best sequence of care for a given patient)
In collaboration with Steven Rosenberg, Chief of Surgery and Immunology at the NCI, and his team, Dr Goy led the effort to bring CAR T cell therapy, the most transforming cancer therapy in over 3 decades, which made our Cancer Center John Theurer, a pioneer of this new and first ever gene therapy and living therapy. Dr Goy believes the future of cancer will be increasingly cell therapy and not pills, as it is empowering and restoring the natural ability of our immune system to cure cancer.
Dr Goy believes we are at an inflection point in medicine due to an unprecedented acceleration in science and technology that is reshaping health care. He co-chaired the Global Council on the Future of Health and Healthcare for the World Economic Forum from 2015 to 2019 and has been participating in the WEF meeting every year since.
Because cancer is a complex, scary, and costly medicine, with an expected increasing incidence estimated at over 60% in the next 25 years, he believes cancer care can be a model for reinventing healthcare delivery. As part of this Dr Goy launched an Institute for Cancer Prevention (Pre-Cancer) and Prevention of Recurrence (Post Cancer). He also wants to develop more chemotherapy at home and empower patients to recover better through wellness.
Dr Goy believes in lifestyle changes and recommends exercise to 100% of his patients during and after cancer treatment. He also believes in the importance of nutrition, and he established a program at the Cancer Center with a demo kitchen where “We can teach patients how to cook, because this is the best way to make them understand we believe in their future” and this program has been very successful. Dr Goy also believes that a plant-based diet can be very impactful in the prevention of cancer and for recovery post therapy. He has implemented this on several hundred patients so far with great results, including some patients, who stopped up to 6 or 7 medications in just 6 months after switching to plant based. Patients are very enthusiastic about this, and he believes that just by exercising and eating better, we could reduce the cost of healthcare by half.
The future of medicine will be more and more towards preemptive medicine, by taking “corrective actions” in people's lifestyles, as we monitor them through molecular wellness at home and in their ecosystem. Up to 50% of cancers are preventable by lifestyle changes – these changes would also reduce the risk of non-communicable chronic diseases dramatically (aging, dementia, autoimmune diseases, etc…)and reduce again the cost of health care. Much of the benefits of better eating is through maintaining a healthy and rich microbiome, i.e. the microorganisms that live in our body (guts, skin for example). It is amazing to realize that almost ½ of the 3 trillion cells we have in our body are non-human cells, but bacteria and fungi mostly, which help constantly modulate our metabolism and our immune system.
Dr Goy believes in the future; food will be medicine, and this is just the beginning.
https://www.foxnews.com/health/food-eat-not-eat-prevent-cancer-according-doctor-nutritionist
Finally, Dr Goy established a cancer survivorship event “Celebrating Life and Liberty” in 2009, which gathered patients and care givers at Ellis Island then Liberty State Park, the Met Life Stadium as it grew up to almost 10,000 pts. Each year he had a celebrity supporting the event as below Aretha Franklin in 2012, where his father came from France and sung before Aretha Franklin.
After completing medical school at the University Joseph Fourier School of Medicine in Grenoble, France, Dr Goy received his training in Hematology/Oncology, and Immunology at The University Hospital System and Pasteur Institute in Paris. He then was on Faculty at Memorial Sloan-Kettering in NY and at M.D. Anderson Cancer Center in Houston, TX for over 15 years before joining HMH and John Theurer Cancer Center, leading one of the largest cancer care programs in the Tri-State Area. Dr Goy is currently enrolled in the E-MBA program at MIT class 2026.
Andre Goy, M.D., Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network
HACKENSACK, N.J., June 9, 2020 — Hackensack Meridian Health has announced the appointment of Andre Goy, M.D., M.S., as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service. In this role, he oversees the delivery of cancer care across the entire Hackensack Meridian Health network, the largest cancer program in New Jersey.
Dr. Goy has been chairman and executive director of John Theurer Cancer Center at Hackensack University Medical Center since 2011 and chair of oncology for Hackensack Meridian Health since 2016. He is also professor of medicine at Georgetown University and professor and chair of oncology at Seton Hall’s Hackensack Meridian School of Medicine. Under his leadership, John Theurer Cancer Center became a member of the Georgetown Lombardi Comprehensive Cancer Center Consortium — one of only 16 research consortia in the nation approved by the National Cancer Institute.
As chief of the Division of Lymphoma since 2005 and holder of the Lydia Pfund Chair for Lymphoma since 2017, he has led New Jersey’s largest program focused on the research and treatment of all types of lymphoma — including Hodgkin disease, non-Hodgkin lymphoma, mantle cell lymphoma, and HIV-associated lymphoma. An internationally renowned lymphoma clinician and researcher, Dr. Goy has trained and/or worked at leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute in Paris.
Dr. Goy is widely known for his work on novel therapies for mantle cell lymphoma, having been principal investigator or co-investigator of the studies behind all four drugs approved to treat mantle cell lymphoma. He first showed evidence of activity of the drug bortezomib in recurrent or persistent mantle cell lymphoma, and then led the pivotal trial of lenalidomide for this disease while participating in the development of both BTK inhibitors ibrutinib and acalabrutinib. These novel agents are transforming the treatment of this disease, which often becomes resistant to standard therapy and has a very poor outcome.
Dr. Goy also initiated CAR T-cell therapy at John Theurer Cancer Center, in collaboration with the team of Steve Rosenberg at the National Cancer Institute. CAR T cell is a form of cellular therapy where a patient’s own immune cells are genetically engineered to force them to attack cancer cells. CAR T cells became the first live therapy approved in 2017 for aggressive lymphoma and leukemia. It is recognized as a revolutionary treatment that is now being expanded to the treatment of other lymphomas, multiple myeloma, and hopefully soon for solid tumors.
He has published extensively and serves as reviewer for many prestigious journals, including New England Journal of Medicine, Journal of Clinical Oncology, Blood, and others. He has co-chaired the Global Council on the Future of Health and Healthcare for the World Economic Forum. Dr. Goy believes that the world is at an inflection point in medicine due exponential and converging advances in science, discovery, and technologies, including artificial intelligence and augmented reality, which will help reshape health monitoring and totally transform care delivery. He has been invited to speak and teach across the globe.
"Thanks to Andre Goy’s leadership, John Theurer Cancer Center has flourished to become one of the nation’s leading cancer care and research centers, and that expertise now extends throughout our entire network," noted Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. "With Dr. Goy at the helm as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service, patients and physicians throughout the state will benefit from his acumen and vision."
Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France before completing his training in hematology oncology in Paris at the Faculty of Medicine Cochin Port Royal. While there, he also received master’s degrees in Tumor Immunology from the Pasteur Institute and in Experimental Oncology from Kremlin Bicetre. Dr. Goy then served on the faculty at Memorial Sloan Kettering Cancer Center and M.D. Anderson Cancer Center before coming to John Theurer Cancer Center.
For more information, please contact Katherine Emmanouilidis, Director, Communications & Public Relations, 551-996-3764.
# # #
About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers.
The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients.
Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey.
John Theurer Cancer Center is a member of the Georgetown Lombardi Comprehensive Cancer Center Consortium, one of just 16 NCI-approved cancer research consortia based at the nation’s most prestigious institutions. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities.
For additional information, please visit www.jtcancercenter.org.
ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.
Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers — Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children’s hospitals - Joseph M. Sanzari Children?s Hospital in Hackensack, K. Hovnanian Children’s Hospital in Neptune; nine community hospitals — Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital — Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.
Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 35,000 team members, and 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.
The network’s notable distinctions include having four hospitals among the top in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet® recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker’s Healthcare’s “150 Top Places to Work in Healthcare/2019” list.
The Hackensack Meridian School of Medicine at Seton Hall University opened in 2018, the first private medical school in New Jersey in more than 50 years, welcomed its second class of 96 students in 2019 to its ON3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.
Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.
###
Physicians’ Education Resource® Announces Andre Goy as the Recipient of the 2019 PER® Educator of the Year
CRANBURY, N.J.--(BUSINESS WIRE)--Nov 19, 2019--
Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), honored Andre H. Goy, M.D., of John Theurer Cancer Center at Hackensack University Medical Center, with the 2019 Educator of the Year award during the 37th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow meeting. The ceremony took place on Wednesday, Nov. 6 at the New York Marriott Marquis in New York City.
“We are so honored to recognize fantastic, dynamic and knowledgeable clinicians and researchers like Dr. Goy through the PER® Educator of the Year award,” said Phil Talamo, president of PER®. “On behalf of PER, we thank Dr. Goy for his tremendous spirit and commitment as a teacher, mentor, enthusiast, and overall gentleman in collaborative education for the treatment of cancers.”
Goy is the chairman and executive director of John Theurer Cancer Center at Hackensack University Medical Center. As chief of the division of lymphoma, he leads New Jersey’s largest program for lymphoma treatment, management and research. He holds the position of Professor and Chair of the oncology department at the Seton Hall - Hackensack Meridian School of Medicine.
The PER® Educator of the Year award highlights the accomplishments of oncology leaders and honors their contributions and efforts to propel the field of medical oncology through innovative and collaborative education.
For more information, click here or find us on Twitter @gotoPER or on Facebook @gotoper.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
PER® Media Contact
Alexandra Ventura, 609-716-7777, ext. 121
aventura@mjhassoc.com
KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA
INDUSTRY KEYWORK: ONCOLOGY HEALTH HOSPITALS OTHER HEALTH OTHER SCIENCE RESEARCH SCIENCE
SOURCE: Physicians' Education Resource
Copyright Bysiness Wire 2019
PUB: 11/19/2019 12:22 PM/DISC: 11/19/2019 12:22 PM
https://www.businesswire.com/news/home/20191119005894/en
Spring 2016, Vol. 1
A MILESTONE CELEBRATION
On Sunday, December 13,2015, patients from the Children’s Cancer Institute joined HackensackUMC President & CEO Robert C. Garrett, Joseph M. Sanzari Children’s Hospital Chairman Dr. Jeffrey Boscamp, and HackensackUMC Foundation EVP/Chief Development Officer Jon Fitzgerald on the field at Metlife Stadium for a special ceremony. Cheered on by the capacity crowd, it was an opportunity to thank the Giants, Eli and Abby Manning, and the Giants fans for their support in raising over $1,000,000 to help Tackle Kids Cancer.
This new charitable effort reached this milestone in less than four months with individual donations from more than 1,000 fans, and major gifts from radio personality Don Imus, the Lisa B. Fishman Foundation, and Eli and Abby Manning. ln addition, the generosity of organizations like Modell’s Sporting Goods, ShopRite, Aquafina, WNBC and a range of other marketing partners helped raise awareness and donations for the program throughout the season.
One hundred percent of funds raised for Tackle Kids Cancer support research and programs at the Children’s Cancer Institute at HackensackUMC. Look for stories on how the funds are being used in this newsletter, and learn how you can join the fight at wwwTackleKidsCancer.org.
LISA B. FISHMAN FOUNDATION MAKES
DONATION TO HACKENSACK UNIVERSITY MEDICAL CENTER FOUNDATION
The Lisa B. Fishman Foundation, a 501(c)(3) organization that provides research funds to improve cancer treatment for people fighting Hodgkin's lymphoma, donated $100,000 to the Hackensack University Medical Center (HUMC) Foundation for the Lisa B. Fishman Hodgkin's Research Fund at the John Theurer Cancer Center at HUMC. The funds were raised at the Foundation's Cruise For A Cause event last August. The donation is a result of a partnership formed between the Lisa B. Fishman Foundation and Andre Goy, M.D., Chairman and Director of the John Theurer Cancer Center and Chief of the Division of Lymphoma. Pictured is Dr. Goy (left) and Lee I. Fishman (right) of Montville, New Jersey, President of the Lisa B. Fishman Foundation and father to its honored namesake, Lisa, who died in 2001 at age 30 of Hodgkin's lymphoma. Dr. Goy and Mr. Fishman are standing in the second floor concourse area of the new John Theurer Cancer facility, which bears the foundation's name.
Winter 2010 Newsletter
Living and Giving Like There’s No Tomorrow:
The Lisa B. Fishman Foundation
Lee Fishman keeps pictures of his daughter, Lisa, near him all day long. They are posted on his office computer, attached to his golf bag, displayed in his living room. “Everywhere I turn, she’s there,“ he said. Lisa’s photos energize Lee to stay focused on helping other parents avoid the loss and pain he lives with.
At age 30, Lisa died in February 2001 of Hodgkin’s lymphoma after a five-year struggle with the cancer. At the time of her death, while completing her Ph.D. in Clinical Psychology at Columbia University, Lisa was a mental health consultant for the New York City Administration for Children Services, helping caseworkers assigned to some of the worst cases of child abuse and neglect. “All Lisa ever wanted to do was help improve the system,” Lee said.
Death has stopped her life’s work, but Lee is determined that Lisa and her memory continue to make a difference. “Lisa was a brilliant young woman and it is devastating that she could not go on to do the things she believed in,” he said.
The Lisa B. Fishman Foundation www.rememberlisa.org was created soon after her death and provides research funds to improve cancer treatment for people fighting Hodgkin’s lymphoma. Lee is very proud of the fact that 94 percent of all funds donated have been available for cancer research.
Great Strides in Research
In 2007, the Foundation established a partnership with Dr. Andre Goy, chief of the Division of Lymphoma Oncology at Hackensack University Medical Center. Dr. Goy and his research team use Foundation funds to explore new, cutting-edge treatments in personalized medicine.
Thanks to this research, patients diagnosed with Hodgkin’s lymphoma no longer are limited to traditional chemotherapy treatments, Lee said. Instead, the researchers can identify custom-made treatments that deliver maximum benefit to an individual.
Usually, most cancer patients receive the same dose of the same medicines in the same way, he explained. But the HUMC researchers can now analyze the molecular makeup of each patient at DNA and protein levels in order to recommend the best treatment specifically for that patient.
The research project is one that the Lisa B. Fishman Foundation hopes will continue indefinitely, Lee added. “The goal is to try to keep other parents from losing a daughter or other family members to this disease,” he said.
Living for Today
Lee said that besides being a devoted daughter, Lisa lived as a huge inspiration and model for her younger sister, Debra Caplan. Since her death, Lisa has inspired her father to live life with a different outlook. “I’ve always been a ’live for today’ type of person,” Lee said, “and this is a perfect example of why we’d better live for today, because we never know what tomorrow is going to bring.”
Family makes her memory into a cause
Attached to Lee Fishman’s golf bag is a weathered photo of a smiling pre-schooler, sporting dark-blonde hair, a Miami Dolphins T-shirt and plenty of personality.
Lisa Fishman will always be her daddy’s little girl, though decades have passed since that particular picture was taken, and five years have passed since Lisa lost her life to Hodgkin’s lymphoma. She was 30 and died fighting, her family said.
Click here to read full article.